Sign In
NASDAQ:INGN
Inogen Stock Earnings Reports
$6.88
+0.150 (+2.23%)
At Close: Apr 23, 2025
Inogen Earnings Calls
Q1 2025
(Upcoming)
| Release date | May 07, 2025 |
| EPS estimate | -$0.520 |
| EPS actual | - |
| Revenue estimate | 79.567M |
| Revenue actual | - |
| Expected change | +/- 5.39% |
Q4 2024
Beat
-$0.410 (26.79%)
| Release date | Feb 25, 2025 |
| EPS estimate | -$0.560 |
| EPS actual | -$0.410 |
| EPS Surprise | 26.79% |
| Revenue estimate | 73.9M |
| Revenue actual | 80.081M |
| Revenue Surprise | 8.36% |
Q3 2024
Beat
-$0.250 (50.98%)
| Release date | Nov 07, 2024 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.250 |
| EPS Surprise | 50.98% |
| Revenue estimate | 73.9M |
| Revenue actual | 88.834M |
| Revenue Surprise | 20.21% |
Q2 2024
Beat
-$0.240 (55.56%)
| Release date | Aug 06, 2024 |
| EPS estimate | -$0.540 |
| EPS actual | -$0.240 |
| EPS Surprise | 55.56% |
| Revenue estimate | 82.5M |
| Revenue actual | 88.765M |
| Revenue Surprise | 7.59% |
Last 4 Quarters for Inogen
Below you can see how INGN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
| Release date | Aug 06, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $8.15 |
| EPS estimate | -$0.540 |
| EPS actual | -$0.240 |
| EPS surprise | 55.56% |
| Date | Price |
|---|---|
| Jul 31, 2024 | $9.25 |
| Aug 01, 2024 | $9.10 |
| Aug 02, 2024 | $8.54 |
| Aug 05, 2024 | $8.18 |
| Aug 06, 2024 | $8.15 |
| Aug 07, 2024 | $11.08 |
| Aug 08, 2024 | $11.67 |
| Aug 09, 2024 | $12.32 |
| Aug 12, 2024 | $11.79 |
| 4 days before | -11.89% |
| 4 days after | 44.66% |
| On release day | 35.95% |
| Change in period | 27.46% |
Q3 2024
Beat
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $9.46 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.250 |
| EPS surprise | 50.98% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $8.69 |
| Nov 04, 2024 | $9.03 |
| Nov 05, 2024 | $9.24 |
| Nov 06, 2024 | $9.57 |
| Nov 07, 2024 | $9.46 |
| Nov 08, 2024 | $11.09 |
| Nov 11, 2024 | $11.02 |
| Nov 12, 2024 | $10.44 |
| Nov 13, 2024 | $10.33 |
| 4 days before | 8.86% |
| 4 days after | 9.20% |
| On release day | 17.23% |
| Change in period | 18.87% |
Q4 2024
Beat
| Release date | Feb 25, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $9.52 |
| EPS estimate | -$0.560 |
| EPS actual | -$0.410 |
| EPS surprise | 26.79% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $10.67 |
| Feb 20, 2025 | $10.28 |
| Feb 21, 2025 | $9.91 |
| Feb 24, 2025 | $9.84 |
| Feb 25, 2025 | $9.52 |
| Feb 26, 2025 | $8.11 |
| Feb 27, 2025 | $7.95 |
| Feb 28, 2025 | $8.33 |
| Mar 03, 2025 | $8.13 |
| 4 days before | -10.78% |
| 4 days after | -14.60% |
| On release day | -14.81% |
| Change in period | -23.81% |
Q1 2025
(Upcoming)
| Release date | May 07, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | -$0.520 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 16, 2025 | $6.88 |
| Apr 17, 2025 | $6.82 |
| Apr 21, 2025 | $6.74 |
| Apr 22, 2025 | $6.73 |
| Apr 23, 2025 | $6.88 |
Inogen Earnings Call Transcript Summary of Q4 2024
Financial Performance:
- Q4 Revenue: Inogen reported revenue of over $80 million in Q4 2024, a 5.5% year-over-year increase. Full-year revenue reached over $335 million, representing a 6.4% increase compared to the previous year.
- Adjusted EBITDA: The company achieved adjusted EBITDA profitability in two quarters of 2024 and reported a negative adjusted EBITDA of $3.6 million in Q4 2024, an improvement from a negative $17.3 million in Q4 2023.
Business Segments:
- Business-to-Business (B2B) Growth: The growth was primarily driven by B2B channels, with domestic B2B revenue increasing by 24.1% and international B2B revenue by 31.5% in Q4. However, direct-to-consumer (D2C) sales declined by 21.3%.
- Rental Revenue: There was a decrease in rental revenue, down 16.5%, influenced by lower average billing rates.
Strategic Initiatives:
- New Products: Inogen launched the Rove 4 portable oxygen concentrator (POC) in October 2024 and received FDA clearance for the Simeox airway clearance device, which they plan to launch in 2025.
- Partnership with Yuwell Medical: Inogen entered into a collaboration with Yuwell, which includes a $27 million investment from Yuwell. This partnership aims to increase distribution in the Chinese market and enhance product offerings in the U.S.
Outlook for 2025:
- Revenue Guidance: For Q1 2025, Inogen expects revenue between $79 million and $81 million, with full-year revenue projected to be between $352 million and $355 million, reflecting a growth of 5%-6% year-over-year.
- Gross Margin Projections: Expected gross margins for 2025 are anticipated to be in the range of 43% to 45%. This is subject to pressure from product introductions and channel mix.
- Adjusted EBITDA Goal: The company aims to approach adjusted EBITDA breakeven in 2025 as they continue to manage expenses diligently.
Market Considerations:
- Payer Mix Shift: Inogen noted a shift towards private payer reimbursement, moving away from traditional Medicare, which they anticipate will continue influencing their rental revenue dynamics.
- Sales Force Changes: The D2C sales force was downsized significantly in 2024 for better profitability, which may continue to impact revenue in the short term.
Management Comments:
President and CEO Kevin Smith expressed confidence in the company's strategic direction and progress, emphasizing their ability to innovate and solve patient needs through new product launches and operational efficiencies.
Conclusion
Inogen's 2024 performance showed signs of recovery and strategic growth, particularly in B2B sectors, with significant efforts made to return to profitability. The partnerships and product developments are key to their long-term outlook, and investors should monitor the company's ability to enhance D2C sales and navigate reimbursement challenges in the evolving market landscape.
Inogen Earnings History
Earnings Calendar
FAQ
When is the earnings report for INGN?
Inogen (INGN) has scheduled its earnings report for May 07, 2025 after the markets close.
What is the INGN price-to-earnings (P/E) ratio?
INGN P/E ratio as of Apr 23, 2025 (TTM) is -4.48.
What is the INGN EPS forecast?
The forecasted EPS (Earnings Per Share) for Inogen (INGN) for the first fiscal quarter 2025 is -$0.520.
What are Inogen's retained earnings?
On its balance sheet, Inogen reported retained earnings of $80.08 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
